Phase 3 trial of everolimus for metastatic renal cell carcinoma

By R. Motzer, B. Escudier, S. Oudard, Thomas E. Hutson, C. Porta, S. Bracarda, V. Grünwald, John A Thompson, R. Figlin, N. Hollaender and 2 more. Cancer, 2010

901 citations recorded by the source corpus.

A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor–tyrosine kinase inhibitors. Final results and analysis of prognostic factors are reported.

Subfields: Molecular Biology, Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c4dd77db7413e913af42f0283c62eb001b876ae0